Termine
Performance
26.11.2021

01.12.21 Vonovia SE
Analystenveranstaltung
01.12.21 VMware, Inc.
Analysts' Conference
01.12.21 VMware, Inc.
Analysts' Conference
01.12.21 TPI Composites, Inc.
Analystenveranstaltung
01.12.21 Semtech Corporation
Analystenveranstaltung
01.12.21 cyan AG
Analystenveranstaltung
01.12.21 B+S Banksysteme Aktiengesellschaft
Hauptversammlung
01.12.21 Deutsche EuroShop AG
DZ Bank Equity Conference, Frankfurt
01.12.21 CLIQ Digital AG
Roadshow
01.12.21 Sberbank
IR Events
01.12.21 Sberbank
IR Events
01.12.21 HomeToGo SE
Credit Suisse 25th Annual Technology Conference

November

KW M D M D F S S
44 1 2 3 4 5 6 7
45 8 9 10 11 12 13 14
46 15 16 17 18 19 20 21
47 22 23 24 25 26 27 28
48 29 30          

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021